| Full text | |
| Author(s): |
Campos, Michel Leandro
;
Alonso, Juliana de Moura
;
Martins, Evelin dos Santos
;
Oliveira, Jonata Augusto
;
Hussni, Carlos Alberto
;
Peccinini, Rosangela Goncalves
Total Authors: 6
|
| Document type: | Journal article |
| Source: | DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE; v. 88, n. 1, p. 95-99, MAY 2017. |
| Web of Science Citations: | 4 |
| Abstract | |
Ceftriaxone is a cephalosporin antibiotic with a potent antimicrobial activity and excellent penetration in most body fluids such as pleural, peritoneal, spinal and brain. These facts contribute to the application of ceftriaxone in the treatment of bacterial peritonitis, an abdominal disorder in veterinary medicine, with potential risk of death. The determination of ceftriaxone levels in plasma and peritoneal fluid may be used to assess the pharmacokinetic profile at various instances of administration and allows observing if the concentrations needed are being achieved. Therefore a method was developed and validated for the determination of ceftriaxone in plasma and peritoneal fluid which after was applied in a pharmacokinetic profile study. The bioanalytical method validation was performed according to widely acceptable experiments. Two horses were used as a model of the method applicability; ceftriaxone was intraperitoneally administered to these animals as a single dose. The plasma and peritoneal fluid analysis were performed using an UHPLC system in reverse phase chromatography mode in fully validated conditions. The methods have shown linearity between 0.49 and 500 mu g/mL for plasma, and between 024 and 500 mu g/mL for peritoneal fluid. The quantitative analysis of ceftriaxone in these matrices allows monitoring of the therapy. This method showed improved sensitivity as well as the quantitation in peritoneal fluid. (C) 2017 Elsevier Inc. All rights reserved. (AU) | |
| FAPESP's process: | 11/11239-9 - Preclinical pharmacokinetics of new drugs and pharmaceuticals forms |
| Grantee: | Rosangela Gonçalves Peccinini |
| Support Opportunities: | Regular Research Grants |